Esther Hong
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
21
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Esther Hong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNOX Bionomics | Maintains: Buy | $10 → $17 | $0.19 | +8,791.21% | 3 | Mar 9, 2023 | |
| ATAI Atai Life Sciences | Initiates: Buy | $18 | $1.08 | +1,566.67% | 2 | Nov 1, 2022 | |
| ACAD ACADIA Pharmaceuticals | Initiates: Hold | $17 | $14.62 | +16.28% | 2 | Nov 1, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $34 | $4.68 | +626.50% | 1 | Nov 1, 2022 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $95 | $87.25 | +8.88% | 2 | Nov 1, 2022 | |
| SAGE Sage Therapeutics | Initiates: Hold | $41 | $5.81 | +605.68% | 2 | Nov 1, 2022 | |
| SPRO Spero Therapeutics | Downgrades: Hold | $2 | $1.29 | +55.04% | 2 | May 20, 2022 | |
| ATHA Athira Pharma | Initiates: Buy | $33 | $0.64 | +5,057.06% | 1 | Apr 21, 2022 | |
| APRE Aprea Therapeutics | Downgrades: Hold | n/a | $3.97 | - | 2 | Aug 16, 2021 | |
| ALDX Aldeyra Therapeutics | Initiates: Buy | $32 | $5.18 | +517.76% | 4 | Dec 16, 2020 |
Bionomics
Mar 9, 2023
Maintains: Buy
Price Target: $10 → $17
Current: $0.19
Upside: +8,791.21%
Atai Life Sciences
Nov 1, 2022
Initiates: Buy
Price Target: $18
Current: $1.08
Upside: +1,566.67%
ACADIA Pharmaceuticals
Nov 1, 2022
Initiates: Hold
Price Target: $17
Current: $14.62
Upside: +16.28%
COMPASS Pathways
Nov 1, 2022
Initiates: Buy
Price Target: $34
Current: $4.68
Upside: +626.50%
Axsome Therapeutics
Nov 1, 2022
Initiates: Buy
Price Target: $95
Current: $87.25
Upside: +8.88%
Sage Therapeutics
Nov 1, 2022
Initiates: Hold
Price Target: $41
Current: $5.81
Upside: +605.68%
Spero Therapeutics
May 20, 2022
Downgrades: Hold
Price Target: $2
Current: $1.29
Upside: +55.04%
Athira Pharma
Apr 21, 2022
Initiates: Buy
Price Target: $33
Current: $0.64
Upside: +5,057.06%
Aprea Therapeutics
Aug 16, 2021
Downgrades: Hold
Price Target: n/a
Current: $3.97
Upside: -
Aldeyra Therapeutics
Dec 16, 2020
Initiates: Buy
Price Target: $32
Current: $5.18
Upside: +517.76%